Population snapshot of the extended-spectrum β-lactamase-producing Escherichia coli invasive strains isolated from a Hungarian hospital

Table 1 Antimicrobial susceptibility of the ESBL-producing E. coli isolates (MIC (mg/L)

Antimicrobial agent		Isolate						MIC breakpoint (mg/L), 2018		MIC breakpoint (mg/L), 2021
Antimicrobial agent		Ec1	Ec2	Ec3	Ec4	Ec5	Ec6	S ≤	R >	S ≤	R >
Cephalosporins	CRO	256	256	256	256	256	256	1	2	1	2
	CAZ	32	32	32	4	4	4	1	4	1	4
	CTX	≥ 256	≥ 256	≥ 256	64	64	≥ 256	1	2	1	2
	CZA	1	0,5	1	0.5	0.25	0.125	8	8	8	8
Carbapenems	ETP	0.125	0.125	0.125	0.008	0.008	0.016	0.5	1	0.5	0.5
	MEM	0.064	0.125	0.064	0.032	0.032	0.032	2	8	2	8
	IMI	0.125	0.125	0.125	0.125	0.125	0.125	2	8	2	4
Fluoroquinolone	CIP	256	64	64	64	64	16	0.25	0.5	0.25	0.5
Aminoglycosides	GM	16	64	64	2	1	0,5	2	4	2	2
	AK	2	4	2	4	4	16	8	16	8	8
	TM	8	32	8	1	2	1	2	4	2	2
Tetracycline	TGC	0.25	0.5	1	0,25	1	0.125	1	2	0.5	0.5
Miscellaneous agents	COL	0.125	0.25	0.125	0.25	0.25	0.064	2	2	2	2
Miscellaneous agents	FOS	0.25	1	4	2	4	1	32	32	32	32

The used antibiotics: ciprofloxacin (CIP), ceftriaxone (CRO), ceftazidime (CAZ), cefotaxime (CTX), ceftazidime/avibactam (CZA), gentamicin (GM), amikacin (AK), tobramycin (TM), tigecycline (TGC), fosfomycin (FOS), colistin (COL), ertapenem (ETP), meropenem (MEM), imipenem (IMI). The EUCAST MIC clinical breakpoints (EUCAST v_8.0 and EUCAST v_11.0) were given for interpretation. All aminoglycosides MIC breakpoint was added for indication E. coli systemic infections. The MIC breakpoint value of ceftriaxone and cefotaxime represent indications other than meningitis

ISSN: 1476-0711